Crackdown on IVF Clinics: CDSCO Tightens Supply Chain for Reproductive Consumables

New regulatory directive mandates that IVF media and specialized lab materials be sold exclusively to fertility centres registered under the ART and Surrogacy Acts.

For years, the fertility industry in India has operated in a grey zone where the demand for parenthood often outpaced the regulatory guardrails meant to protect patients. That is changing. The Central Drugs Standard Control Organisation (CDSCO) has now issued a definitive directive, effectively choking the supply chain for clinics operating outside the government’s oversight.

Under the new order, manufacturers and importers are strictly prohibited from selling IVF media, cryopreservation reagents, and other essential consumables to any facility not registered under the Assisted Reproductive Technology (ART) and Surrogacy Acts of 2021. By tethering the supply of these critical laboratory tools to formal legal registration, the health regulator is moving to purge unregistered entities from the reproductive healthcare ecosystem.

Why the move was necessary

These laboratory solutions—used to handle, preserve, and culture eggs, sperm, and embryos—are not mere medical supplies; they are the backbone of any IVF procedure. Because these products are categorized as medical devices under the 2017 Medical Devices Rules, their distribution was always intended to be monitored. However, the regulator found that these specialized products were frequently flowing into the hands of fly-by-night clinics, raising significant red flags regarding patient safety and the ethical handling of biological material.

By forcing a link between the supply of consumables and the registration status of fertility centres, the CDSCO is essentially using the supply chain to enforce compliance. Clinics that have yet to secure their credentials under the ART and Surrogacy Acts will now find themselves unable to source the basic materials required to function.

The bigger picture

This is a clear signal that the era of "self-regulation" in India’s booming fertility sector is drawing to a close. For too long, the lack of standardized practices in smaller, unregistered clinics has been a source of anxiety for policymakers. By mandating that only registered clinics can procure these consumables, the government is creating a de facto filter.

It suggests a broader pattern: rather than just chasing clinics post-facto, authorities are now controlling the inputs to ensure that only compliant, transparent, and accountable centres can participate in the market. For patients, this is a long-overdue layer of protection. For the industry, it marks the end of the road for those who have operated in the shadows of the law, as they now face a total blockade on the very tools they need to operate.

The directive has already been disseminated to state and Union Territory licensing authorities, along with zonal offices, ensuring that the clampdown is enforced from the point of manufacture down to the local clinic level.